DK1409692T3 - Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine - Google Patents

Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine

Info

Publication number
DK1409692T3
DK1409692T3 DK02770043T DK02770043T DK1409692T3 DK 1409692 T3 DK1409692 T3 DK 1409692T3 DK 02770043 T DK02770043 T DK 02770043T DK 02770043 T DK02770043 T DK 02770043T DK 1409692 T3 DK1409692 T3 DK 1409692T3
Authority
DK
Denmark
Prior art keywords
rsv
vaccine
protein
peptides derived
novel peptides
Prior art date
Application number
DK02770043T
Other languages
Danish (da)
English (en)
Inventor
Nathalie Corvaia
Alain Beck
Gilquin Helene Plotnicky
Ngoc Thien Nguyen
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Application granted granted Critical
Publication of DK1409692T3 publication Critical patent/DK1409692T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK02770043T 2001-07-20 2002-07-19 Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine DK1409692T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0109731A FR2827605B1 (fr) 2001-07-20 2001-07-20 Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
PCT/FR2002/002599 WO2003010317A1 (fr) 2001-07-20 2002-07-19 Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin

Publications (1)

Publication Number Publication Date
DK1409692T3 true DK1409692T3 (da) 2009-02-02

Family

ID=8865750

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02770043T DK1409692T3 (da) 2001-07-20 2002-07-19 Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine

Country Status (16)

Country Link
US (3) US7309494B2 (es)
EP (1) EP1409692B1 (es)
JP (1) JP4310184B2 (es)
CN (1) CN1556857A (es)
AT (1) ATE408696T1 (es)
AU (1) AU2002336148B8 (es)
BR (1) BR0211296A (es)
CA (1) CA2455360A1 (es)
DE (1) DE60228971D1 (es)
DK (1) DK1409692T3 (es)
ES (1) ES2314102T3 (es)
FR (1) FR2827605B1 (es)
MX (1) MXPA04000597A (es)
PT (1) PT1409692E (es)
WO (1) WO2003010317A1 (es)
ZA (1) ZA200400916B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2426312C (en) 2000-10-18 2014-01-14 Ralph A. Tripp Compositions and methods for modulating rsv infection and immunity
EP1768993A4 (en) * 2004-06-16 2008-07-23 Univ Johns Hopkins CYSTEINE-RICH REGION OF SYNCYTIAL RESPIRATORY VIRUS AND METHODS OF USE THEREOF
EP1972348A1 (en) * 2007-03-14 2008-09-24 Pierre Fabre Medicament Novel vaccine composition for the treatment of respiratory infectious diseases
KR20110061611A (ko) 2008-09-18 2011-06-09 노파르티스 아게 백신 보조제 조합
US8846056B2 (en) 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
RU2012131014A (ru) * 2009-12-21 2014-01-27 Корнелл Юниверсити Композиции нового пневмовируса и способы их применения
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
ES2630029T3 (es) 2010-12-14 2017-08-17 Glaxosmithkline Biologicals Sa Análisis de citometría de flujo de materiales adsorbidos en sales metálicas
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
WO2012138774A2 (en) 2011-04-04 2012-10-11 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
ES2395677B1 (es) * 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822947B1 (en) 2012-03-07 2016-08-03 GlaxoSmithKline Biologicals SA Arginine salts of a tlr7 agonist
CN104159602B (zh) 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
MY171498A (en) 2012-08-01 2019-10-15 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
CN105085684B (zh) * 2014-05-14 2020-04-17 上海亨臻实业有限公司 Pcsk9靶向重组疫苗设计及其应用
WO2016160166A1 (en) 2015-03-30 2016-10-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic rsv polypeptides
EP3416975A4 (en) * 2016-02-16 2019-08-21 The University of Queensland NEW ALPHA-CONOTOXIN PEPTIDES
CN109232737A (zh) * 2016-03-01 2019-01-18 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
AU2020227545B2 (en) 2019-02-28 2023-10-19 Km Biologics Co., Ltd. RSV F/G chimeric vaccine
US11360877B2 (en) * 2020-09-14 2022-06-14 International Business Machines Corporation Forming microservices from monolithic applications
WO2024084785A1 (ja) * 2022-10-20 2024-04-25 一般財団法人阪大微生物病研究会 Ｒｓウイルスワクチンとしての利用に好適な組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3689622T2 (de) 1986-01-14 1994-06-16 Univ North Carolina Impfstoffe gegen menschliche respiratorische viren.
US5223254A (en) 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AUPO026596A0 (en) 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
FR2766192B1 (fr) 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
FR2776521B1 (fr) 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale

Also Published As

Publication number Publication date
JP4310184B2 (ja) 2009-08-05
US20090036367A1 (en) 2009-02-05
FR2827605B1 (fr) 2004-07-16
US20040175395A1 (en) 2004-09-09
EP1409692B1 (fr) 2008-09-17
US7309494B2 (en) 2007-12-18
PT1409692E (pt) 2008-12-26
MXPA04000597A (es) 2004-04-20
US7524627B2 (en) 2009-04-28
DE60228971D1 (de) 2008-10-30
AU2002336148B8 (en) 2008-06-19
FR2827605A1 (fr) 2003-01-24
ZA200400916B (en) 2004-08-25
EP1409692A1 (fr) 2004-04-21
US20090181042A1 (en) 2009-07-16
BR0211296A (pt) 2004-09-14
AU2002336148B2 (en) 2007-12-13
CN1556857A (zh) 2004-12-22
ES2314102T3 (es) 2009-03-16
CA2455360A1 (fr) 2003-02-06
WO2003010317A1 (fr) 2003-02-06
ATE408696T1 (de) 2008-10-15
JP2005511010A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
CY1123152T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
CY1118090T1 (el) Αντιγονα ανασυνδυασμενου rsv
ATE426412T1 (de) Adjuvante influenza-vakzine
ATE542829T1 (de) Impfstoff
MXPA05009580A (es) Vacuna contra el virus de la influenza.
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
IS7658A (is) Bóluefna samsetningar sem samanstanda af fitufásykrum af L2 og/eða L3 ónæmisgerð úr 1gtB mengishnettlu
DK1185691T3 (da) Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
SI1881845T1 (sl) Cepiva proti virusu Nipah
MX2014012234A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
GB2386072A (en) Novel vaccine
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
EA200700496A1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
ATE507286T1 (de) Immunisierung von fischen gegen virusinfektion
WO2002058725A3 (fr) Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
WO2006024240A3 (es) Composición vacunal contra el virus de la hepatitis c.
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
EP1667634A4 (en) ANTHRAX VACCINE
ATE515270T1 (de) Phep, eine aminosäurepermease von staphylococcus aureus
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides